FDA Accepts Praxis New Drug Application for Essential Tremor, Putting Ulixacaltamide on Review Countdown
A small-molecule drug designed specifically for essential tremor has moved from the uncertainty of clinical trials to FDA review; whether it can reshape a treatment landscape that has long had limited options could be revealed as early as early 2027.